Pharmaceuticals & Biotechnology Editor | 03/10/2010
An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals on bacterial fatty-acid synthesis as a target for AFN-1252: a novel and selective-spectrum antibiotic for the treatment of Staphylococcal infection.
Download PDF Attachment
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More